BPI-9016M, a novel c-Met inhibitor, in pretreated advanced solid tumor: Results from a first-in-human, phase I, dose-escalation study.

被引：0
|
作者：
Hu, Xingsheng
Zheng, Xin
Mo, Hongnan
Cui, Xinge
Ding, Lieming
Tan, Fenlai
Hu, Pei
Shi, Yuankai
机构：
[1] Chinese Acad Med Sci, Beijing Key Lab Clin Study Anticancer Mol Targete, Canc Hosp, Natl Canc Ctr, Beijing, Peoples R China
[2] Peking Union Med Coll, Beijing, Peoples R China
[3] Peking Union Med Coll Hosp, Peking Union Med Coll, Clin Pharmacol Res Ctr, Beijing, Peoples R China
[4] Chinese Acad Med Sci, Beijing, Peoples R China
[5] Peking Union Med Coll Hosp, Beijing, Peoples R China
[6] Betta Pharmaceut Co Ltd, Hangzhou, Zhejiang, Peoples R China
[7] Peking Union Med Coll Hosp, Clin Pharmacol Res Ctr, Beijing, Peoples R China
[8] Chinese Acad Med Sci, Beijing Key Lab Clin Study Anticancer Mol Targete, Canc Hosp, Dept Med Oncol,Natl Canc Ctr, Beijing, Peoples R China
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2018年 / 36卷 / 15期
关键词：
D O I：
10.1200/JCO.2018.36.15_suppl.e21108
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
e21108
引用
收藏
页数：1
相关论文
共 50 条
  • [21] A First-in-human, Dose-escalation Study of the Methionine Aminopeptidase 2 Inhibitor M8891 in Patients with Advanced Solid Tumors
    Carducci, Michael A.
    Wang, Ding
    Habermehl, Christina
    Bodding, Matthias
    Rohdich, Felix
    Lignet, Floriane
    Duecker, Klaus
    Karpenko, Oleksandr
    Pudelko, Linda
    Gimmi, Claude
    LoRusso, Patricia
    CANCER RESEARCH COMMUNICATIONS, 2023, 3 (08): : 1638 - 1647
  • [22] A phase I, first-in-human, dose-escalation and dose expansion study of the multitarget kinase inhibitor TT-00420 in patients with advanced solid tumors.
    Piha-Paul, Sarina Anne
    Wan, Qunfang
    Xiong, Wendy
    Peng, Peng
    Yang, Xiaoju
    Wu, Henry
    Ngo, Brenda
    Wu, Frank
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
  • [23] First-in-Human RNA Polymerase I Transcription Inhibitor CX-5461 in Patients with Advanced Hematologic Cancers: Results of a Phase I Dose-Escalation Study
    Khot, Amit
    Brajanovski, Natalie
    Cameron, Donald P.
    Hein, Nadine
    Maclachlan, Kylee H.
    Sanij, Elaine
    Lim, John
    Soong, John
    Link, Emma
    Blombery, Piers
    Thompson, Ella R.
    Fellowes, Andrew
    Sheppard, Karen E.
    McArthur, Grant A.
    Pearson, Richard B.
    Hannan, Ross D.
    Poortinga, Gretchen
    Harrison, Simon J.
    CANCER DISCOVERY, 2019, 9 (08) : 1036 - 1049
  • [24] Phase I, First-in-Human, Dose-Escalation Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Vorolanib in Patients with Advanced Solid Tumors
    Bendell, Johanna C.
    Patel, Manish R.
    Moore, Kathleen N.
    Chua, Cynthia C.
    Arkenau, Hendrik-Tobias
    Dukart, Gary
    Harrow, Kim
    Liang, Chris
    ONCOLOGIST, 2019, 24 (04): : 455 - E121
  • [25] A phase 1 dose-escalation study of the ABN401 (c-MET inhibitor) in patients with solid tumors.
    Lee, Dae Ho
    Roohullah, Aflah
    Cho, Byoung Chul
    Lemech, Charlotte Rose
    De Souza, Paul L.
    Millward, Michael
    Choi, Jun Young
    Park, Kyung Eui
    Kim, Na Young
    Kim, EuiYoung
    Lee, Saehyung
    Kim, YeongMun
    Shin, Youngkee
    Han, Ji-Youn
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
  • [26] First-in-Human Phase I, Dose-Escalation and -Expansion Study of Telisotuzumab Vedotin, an Antibody-Drug Conjugate Targeting c-Met, in Patients With Advanced Solid Tumors (vol 36, pg 3298, 2018)
    Strickler, J. H.
    Weekes, C. D.
    Nemunaitis, J.
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (03) : 261 - 261
  • [27] First-in-human phase 1, dose-escalation and -expansion study of ABBV-399, an antibody-drug conjugate (ADC) targeting c-Met, in patients (pts) with advanced solid tumors
    Angevin, E.
    Kelly, K.
    Heist, R.
    Morgensztern, D.
    Weekes, C.
    Bauer, T. M.
    Ramanathan, R. K.
    Nemunaitis, J.
    Fan, X.
    Olyaie, O.
    Parikh, A.
    Reilly, E.
    Afar, D.
    Naumovski, L.
    Strickler, J.
    ANNALS OF ONCOLOGY, 2016, 27
  • [28] First-in-human (FIH) phase I study of GST-HG161, a potent and highly selective c-met inhibitor, in patients with advanced solid tumor.
    Li, Jin
    Guo, Ye
    Xue, Junli
    Wu, Wenqiang
    Chen, Shikui
    Tang, Yanan
    Xu, Xiongbin
    Li, Gang
    Hu, Lihong
    Lin, Yunfei
    Shen, Liang
    Xia, Yuanfeng
    Chan, Chi-Chung
    Wang, Zhouchong
    Ni, Dawen
    Ding, Charles
    Chen, Shuhui
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [29] Results of a first-in-human, dose-escalation phase 1 study of the ERK1/2 inhibitor ATG-017 in patients with advanced solid tumors
    Wahlroos, Sara
    Teng, Christina
    Tran, Ben
    Voskoboynik, Mark
    Gan, Hui Kong
    Spencer, Andrew
    Kudva, Anupa
    Song, Ming
    Lynch, Kevin
    Yu, Zhinuan
    Desai, Jayesh
    Lemech, Charlotte Rose
    Lifehouse, Chris O'Brien
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [30] Final results: A dose escalation phase I study of ARQ 197, a selective c-Met inhibitor, in patients with metastatic solid tumors
    Mekhail, T.
    Rich, T.
    Rosen, L.
    Chai, F.
    Semic-Suka, Z.
    Savage, R. E.
    Senzer, N.
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
12345